GYRE
Gyre Therapeutics Inc.
7.00$
-4.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 290.5% | 340.5% | 2,645.4% | 17.0% | 2,483.3% | – | 43.7% | 104.5% | 4.7% | 4.1% | 3.7% | 4.6% | |
| -190.5% | -240.5% | -2,545.4% | 83.0% | -2,383.3% | – | 56.3% | -4.5% | 95.3% | 95.9% | 96.3% | 95.4% | |
| 290.5% | 340.5% | 2,896.0% | 1,262.0% | 357,900.0% | – | 252.9% | 880.0% | 16.3% | 12.1% | 11.4% | 11.7% | |
| 223.7% | 548.2% | 2,321.3% | 981.6% | 205,900.0% | – | 77.2% | 256.5% | 17.0% | 12.9% | 15.2% | 17.8% | |
| 476.7% | 888.7% | 5,217.3% | 2,226.6% | 563,800.0% | – | 330.1% | 1,136.5% | 86.3% | 155.2% | 81.0% | 85.5% | |
| -414.2% | -788.7% | -5,117.3% | -2,143.6% | -563,700.0% | – | -273.9% | -1,141.0% | 9.0% | -59.3% | 15.3% | 9.9% | |
| 1.3% | 84.5% | – | – | – | – | – | 3.0% | 0.7% | – | – | – | |
| -364.8% | -843.5% | -4,246.9% | -2,118.0% | -500,916.7% | – | -268.5% | -1,198.3% | 9.2% | -67.8% | 22.0% | 12.4% | |
| 192.2% | 29.6% | 772.9% | -17.0% | 62,783.3% | – | -3.3% | -0.5% | 5.0% | 7.5% | 5.0% | 3.9% | |
| -1,799.4% | -843.5% | -4,246.9% | -2,118.0% | -500,916.7% | – | -265.1% | -1,198.3% | 2.3% | -81.9% | 11.4% | 4.3% | |
| -376.7% | -732.2% | -5,019.8% | -2,126.6% | -563,700.0% | – | -267.8% | -1,194.4% | 10.3% | 17.9% | 16.8% | 14.5% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.